Rich Heyman, Metacrine chairman (ARCH)

Metacrine, a Rich Hey­man biotech tar­get­ing NASH and oth­er liv­er dis­eases, rais­es $85M from IPO

A Rich Hey­man-backed start­up fo­cus­ing on NASH treat­ments, as well as oth­er liv­er, GI and meta­bol­ic dis­eases, is set to start trad­ing Wednes­day and join …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.